Vol 7, No 3 (2016)
Case report
Published online: 2017-02-23
Pomalidomide in combination with clarithromycin and dexamethasone for double refractory plasma cell myeloma — a case report and review of literature
Hematologia 2016;7(3):250-256.
Abstract
Pomalidomide is a new immunomodulatory drug used for treatment of plasma cell myeloma (PCM). In this paper, we describe a case report of a woman with PCM who was double refractory to bortezomib and lenalidomide, and was subsequently treated with pomalidomide with clarithromycin and dexamethasone.
Keywords: refractory plasma cell myelomapomalidomide
References
- Kumar SK, Lee JH, Lahuerta JJ, et al. International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012; 26(1): 149–157.
- Usmani S, Ahmadi T, Ng Y, et al. Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD. Oncologist. 2016 [Epub ahead of print]; 21: 1355–1361.
- Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010; 28(33): 4976–4984.
- Hoffmann M, Kasserra C, Reyes J, et al. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol. 2013; 71(2): 489–501.
- Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009; 27(21): 3518–3525.
- Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol. 2005; 74(3): 212–216.
- Meadows JP, Mark TM. Management of double-refractory multiple myeloma. Curr Hematol Malig Rep. 2013; 8(4): 253–260.
- Jakubowiak AJ, Siegel DS, Martin T, et al. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res. 2012; 18(17): 4830–4840.
- Ludwig H, Masszi T, Petrucci MT, et al. Carfilzomib (K) vs low-dose corticosteroids and optional cyclophosphamide (Cy) in patients (pts) with relapsed and refractory multiple myeloma (RRMM): results from a phase 3 study (FOCUS). Ann Oncol. 2014; 25: 1–41.
- Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016; 387(10027): 1551–1560.
- Lee HC, Shah JJ, Orlowski RZ. Novel approaches to treatment of double-refractory multiple myeloma. Am Soc Clin Oncol Educ Book. 2013: 302–306.
- Wolf JL, Siegel D, Goldschmidt H, et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012; 53(9): 1820–1823.
- Nooka AK, Kastritis E, Dimopoulos MA, et al. Treatment options for relapsed and refractory multiple myeloma. Blood. 2015; 125(20): 3085–3099.
- Gerrie AS, Mikhael JR, Cheng Lu, et al. D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma. Br J Haematol. 2013; 161(6): 802–810.
- Ludwig H, Kasparu H, Leitgeb C, et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood. 2014; 123(7): 985–991.
- Sellner L, Heiss C, Benner A, et al. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. Cancer. 2013; 119(13): 2438–2446.
- Gahrton G, Svensson H, Cavo M, et al. European Group for Blood and Marrow Transplantation. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001; 113(1): 209–216.
- Dmoszyńska A, Walter-Croneck A, Usnarska-Zubkiewicz L, et al. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2015. Acta Haematologica Polonica. 2015; 46(3): 159–211.
- Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009; 69(18): 7347–7356.
- Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 2007; 67(2): 746–755.
- Li S, Pal R, Monaghan SA, et al. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood. 2011; 117(19): 5157–5165.
- Terpos E, Dimopoulos MA, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia. 2007; 21(9): 1875–1884.
- Anderson G, Gries M, Kurihara N, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood. 2006; 107(8): 3098–3105.
- Munemasa S, Sakai A, Kuroda Y, et al. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int. J. Oncol. 2008; 33: 129–136.
- Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2013; 14(11): 1055–1066.
- Mark TM, Boyer A, Yadlapati S, et al. Clapd (clarithromycin, pomalidomide, dexamethasone) therapy in relapsed or refractory multiple myeloma overcomes negative prognostic impact of adverse cytogenetics and prior resistance to lenalidomide and bortezomib. Blood. 2015; 126: 4232.
- Mark T.M., Boyer A., Rossi A.C. i wsp. ClaPd (clarithromycin/ /[Biaxin ® ], pomalidomide, dexamethasone). Therapy in relapsed or refractory multiple myeloma. Oral presented at: 54 th Annual Meeting of the American Society of Hematology (ASH) Atlanta, 08-11.12.2012.
- Morris TCM, Kettle PJ, Drake M, et al. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma. Br J Haematol. 2008; 143(3): 349–354.
- Ghosh N, Tucker N, Zahurak M, et al. Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma. Am J Hematol. 2014; 89(8): E116–E120.
- Rossi A, Mark T, Jayabalan D, et al. BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood. 2013; 121(11): 1982–1985.
- Larocca A, Montefusco V, Bringhen S, et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood. 2013; 122(16): 2799–2806.
- Berenson J., Stampleman L., Bessudo A. i wsp. A phase 1/2 trial of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma [abstract]. Proceedings of the 56 th Annual Meeting and Exposition of the American Society of Hematology (ASH) 06-09.12.2014.
- Rosenbaum C.A., Kukreti V., Zonder J. i wsp. Phase 1b/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients with lenalidomide-exposed and/or- refractory but proteasome inhibitors-naïve or -sensitive multiple myeloma: a multiple myeloma research consortium multi-center study [abstract]. Proceedings of the 56 th Annual Meeting and Exposition of the American Society of Hematology (ASH) San Francisco, 06-09.12.2014.
- Shah J.J., Standtmauer E.A., Abonour R. i wsp. A multi-center phase I/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma [oral]. Oral presented at the 55 th Annual Meeting of the American Society of Hematology (ASH) New Orleans, 7-10.12.2013.
- Shah J.J., Standtmauer E.A., Abonour R. i wsp. A multi-center phase I/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma [oral]. Oral presented at the 54 th Annual Meeting of the American Society of Hematology (ASH) Atlanta, 08-11.12.2012.
![](https://journals.viamedica.pl/plugins/generic/popups/images/icons/close.png)